Trade Summary

2 months ago, Schimmel Paul, serving as Dir at Atyr Pharma Inc (ATYR), purchased 1,000,000 shares at $0.91 per share, for a total transaction value of $911,801.00. Following this transaction, Schimmel Paul now holds 2,101,056 shares of ATYR.

This purchase represents a 91.00% increase in Schimmel Paul's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, October 8, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, October 9, 2025, 1 day after the trade was made.

Atyr Pharma Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.